Therapy

Voyager Therapeutics to Report Second Quarter 2020 Financial Results and Participate in Upcoming Investor Conferences

Branches of biology, Life sciences, Biology, Emerging technologies, Gene delivery, Medical genetics, Molecular biology, Biotechnology, Gene therapy, Therapy
Monday, August 3, 2020 - 9:30pm

CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will report its second quarter 2020 financial results and corporate updates on Monday, August 10, 2020, before the open of the U.S. financial markets.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will report its second quarter 2020 financial results and corporate updates on Monday, August 10, 2020, before the open of the U.S. financial markets.
  • Additionally, the company will participate in the following virtual investor conferences in August:
    Monday, August 10 at 3:30 p.m.
  • Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases.
  • Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques.

PRN and MemorialCare Announce Joint-Venture to Operate Largest Regional Network of Comprehensive Physical Therapy Clinics

General Health, Health, Physical therapy, Health, Medical specialties, Rehabilitation, Therapy, Physical therapy
Monday, August 3, 2020 - 6:00pm

This joint venture represents one of the largest consolidations of physical therapy services under one health system in the region.

Key Points: 
  • This joint venture represents one of the largest consolidations of physical therapy services under one health system in the region.
  • Under the agreement, MemorialCare will partner with PRNs local physical therapy centers under the flagship brand, California Rehabilitation and Sports Therapy (Cal Rehab).
  • Cal Rehab is the second largest physical therapy provider in Los Angeles & Orange County, California.
  • Physical Rehabilitation Network, LLC., (PRN) is a privately held physical therapy organization based in Carlsbad, California.

TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program in Purchase Agreement for up to $250 million in Milestone Payments plus Royalties on Future Net Sales

Health sciences, Health, RTT, Articles, Cancer, Melanoma, Therapy
Monday, August 3, 2020 - 1:00pm

Promising clinical study data with this investigational agent has been shown as an important component of combination immuno-therapy for the treatment of advanced cutaneous melanoma.

Key Points: 
  • Promising clinical study data with this investigational agent has been shown as an important component of combination immuno-therapy for the treatment of advanced cutaneous melanoma.
  • We will continue to focus our resources and efforts to drive value through the advancement of our vaccine business.
  • We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
  • Information on Dynavax's website at www.dynavax.com is not incorporated by reference in our current periodic reports with the SEC.

VBL Therapeutics to Report Second Quarter 2020 Financial Results on August 13

Health, Clinical medicine, RTT, Oncology, Ofranergene obadenovec, Ovarian cancer, Cancer, Therapy, Targeted therapy
Monday, August 3, 2020 - 1:00pm

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.

Key Points: 
  • Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.
  • VBLs lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors.
  • It is conveniently administered as an IV infusion once every two months.
  • Ofranergene obadenovec is currently being studied in a VBL-sponsored phase 3 potential registration trial for platinum-resistant ovarian cancer.

Naropa Community Counseling Offers Community Coronavirus-Specific Support

Articles, Health, Psychotherapy, Therapy, Community, Community counseling, Mental health, Telehealth, Clinical mental health counseling, Contemplative education
Friday, July 31, 2020 - 10:51pm

Naropa Community Counseling (NCC) has provided ongoing therapy through telehealth throughout this crisis, but as the crisis has worn on, it has become clear that the needs for support are growing.

Key Points: 
  • Naropa Community Counseling (NCC) has provided ongoing therapy through telehealth throughout this crisis, but as the crisis has worn on, it has become clear that the needs for support are growing.
  • For those wishing to support the mental health of community members that are struggling economically, NCC offers the Client Access Fund.
  • Naropa Community Counseling integrates contemplative approaches with modern clinical practice to assist our clients in reaching their highest level of emotional and mental well-being.
  • Naropa Community Counseling serves Boulder and Front Range residents with low to moderate income, with sliding scale services from $3090.

Intraoperative Radiation Therapy Market - Growth, Trends & Forecast 2020 - ResearchAndMarkets.com

Professional services, Consulting, Medicine, Health, Intraoperative radiation therapy, Intraoperative electron radiation therapy, Radiation therapy, Therapy, Surgery, Targeted intra-operative radiotherapy, Electron therapy
Friday, July 31, 2020 - 9:50am

The "Intraoperative Radiation Therapy Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intraoperative Radiation Therapy Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • Intraoperative radiation therapy (IORT) is an intensive radiation treatment that's administered during surgery.
  • Electron Intraoperative radiation therapy or Intraoperative electron radiation therapy (IOERT) is the application of electron radiation directly to the residual tumor or tumor bed during cancer surgery.
  • Hence, as high demand is met by the presence of global players in the region, the market is further expected to increase.

REGENXBIO To Host Conference Call on August 6 to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights

Branches of biology, Life sciences, Biology, Biotechnology, Bioethics, Gene therapy, Molecular biology, Therapy, Curative
Thursday, July 30, 2020 - 9:05pm

ET to discuss its financial results for the quarter ended June 30, 2020, and recent operational highlights.

Key Points: 
  • ET to discuss its financial results for the quarter ended June 30, 2020, and recent operational highlights.
  • To access the live call by phone, dial (800) 708-4539 (domestic) or (800) 619-6396 (international) and enter the passcode 49857700.
  • To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com .
  • REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.

Justin Zamirowski Appointed as Chief Commercial Officer

Health sciences, Health, Articles, Diabetes, Diabetes management, Cognitive behavioral therapy, Therapy
Thursday, July 30, 2020 - 7:45pm

Justin brings over 20 years of diverse biotech and pharma commercialization experience across multiple therapeutic areas and classes.

Key Points: 
  • Justin brings over 20 years of diverse biotech and pharma commercialization experience across multiple therapeutic areas and classes.
  • As Chief Commercial Officer, Justin will lead Better Therapeutics' efforts in market development and commercial operations to prepare for the upcoming launch of BT-001, a prescription digital therapeutic delivering nutritional cognitive behavior therapy (nutritional CBT), a novel form of behavioral therapy.
  • BT-001 is intended to help adult patients with type 2 diabetes, under the guidance of their physician, improve glycemic control by lowering HbA1c.
  • Prior to Guidehouse, Justin held commercial leadership roles at Edge Therapeutics and Otsuka, where he launched products across cardiovascular, central nervous system, and oncology therapeutic areas.

Expression Therapeutics Announces Bill Swaney as VP of Manufacturing and the Construction of Cell and Gene Therapy Manufacturing

Health, Drug discovery, Health policy, Medicinal chemistry, Therapy, Articles, Branches of science
Thursday, July 30, 2020 - 3:27pm

ATLANTA, July 30, 2020 /PRNewswire/ --Expression Therapeutics has announced the appointment of Bill Swaney as the Vice President of Manufacturing.

Key Points: 
  • ATLANTA, July 30, 2020 /PRNewswire/ --Expression Therapeutics has announced the appointment of Bill Swaney as the Vice President of Manufacturing.
  • Mr. Swaney is an internationally recognized expert in GMP cell and gene therapy manufacturing and has conducted over 70 GMP production runs for academic and commercial clients.
  • "We are pleased to welcome Bill, a pioneer in cell and gene therapy manufacturing, to Expression Therapeutics.
  • Expression Therapeutics has also announced today the construction of a 43,000-sq ft manufacturing facility in Cincinnati, Ohio.

Molecular Therapy Peer-Reviewed Article by AGT and NIAID Outlines Preclinical Data, Shows Potential for HIV Functional Cure

Branches of biology, Medical specialties, Health, HIV/AIDS, Pandemics, HIV, Therapy, CD4, T helper cell, HIV/AIDS research, Gene therapy
Thursday, July 30, 2020 - 3:52pm

Through a collaboration agreement initiated in 2019 between AGT and NIAID, government researchers studied the mechanism of action for AGT103-T , AGTs proprietary, genetically modified, autologous cell product, to define its potential impacts on HIV.

Key Points: 
  • Through a collaboration agreement initiated in 2019 between AGT and NIAID, government researchers studied the mechanism of action for AGT103-T , AGTs proprietary, genetically modified, autologous cell product, to define its potential impacts on HIV.
  • HIV disease is characterized by the extensive loss of and failure to reconstitute HIV-specific CD4 T cells, which leads to chronic infection and disease.
  • Link to Molecular Therapy Article:
    American Gene Technologies (AGT) is a gene and cell therapy company with a proprietary gene-delivery platform for rapid development of cell and gene therapies to cure infectious diseases, cancers, and inherited disorders.
  • The Company expects to take its patented lead candidate for an HIV cure to the clinic in 2020.